Med24
Clinical Medicine 14. 10. 2026 • 2 min read • medical-news

Real-World Treatment Choices for AMD

Poor adherence to anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) remains a major limitation of existing therapies, a review of a large clinical database showed. Almost 40% of patients stopped treatment...

Real-World Treatment Choices for AMD

A review of a large clinical database revealed that approximately 40% of patients with neovascular age-related macular degeneration (nAMD) stopped VEGF therapy within the first year, increasing to a majority by the end of the second year. Visual acuity declined with decreasing injection frequency. Delayed treatment initiation was associated with poorer outcomes. Non-persistence in VEGF treatment was linked to worse fibrosis and atrophy.

A separate study analyzing the Vestrum Health Retina Database of 201,768 eyes found that 38.9% of patients became non-persistent within 12 months, with a corresponding decrease in the number of intravitreal injections. A trend analysis showed a surge in bevacizumab use, alongside increased use of biosimilars, and variation in therapy choices by indication. Switching to bevacizumab after 2023 was associated with a decline in visual acuity, as reported in a poster presentation.

Sponsored content

The analysis of the Vestrum database in 2025 indicated that bevacizumab and faricimab accounted for nearly half of all nAMD injections, while biosimilar aflibercept-ayyh was the most common biosimilar used. The increased use of bevacizumab was attributed to patient challenges related to co-pay support.”} p>

Original Scientific Source
medical-news
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement